Abdominal Pain News and Research RSS Feed - Abdominal Pain News and Research

Abdominal pain is traditionally described by its chronicity (acute or chronic), its progression over time, its nature (sharp, dull, colicky), its distribution (by various methods, such as abdominal quadrant (left upper quadrant, left lower quadrant, right upper quadrant, right lower quadrant) or other methods that divide the abdomen into nine sections), and by characterization of the factors that make it worse, or alleviate it.
Discovery takes researchers one step closer to preventing C. diff

Discovery takes researchers one step closer to preventing C. diff

Exposure to specific antibiotics is linked to the development of certain strains of antibiotic-resistant C. difficile, one of the fastest growing bacteria superbugs, according to a new study published by Stuart Johnson, MD, of Loyola University Health System, Loyola University Chicago Stritch School of Medicine and the Hines VA Medical Hospital. [More]
Researchers use new method to assess quality of colonoscopies performed in outpatient facilities

Researchers use new method to assess quality of colonoscopies performed in outpatient facilities

Colonoscopies are now a routine preventive diagnostic test for millions of Americans each year. While rates are low, complications like perforation, bleeding, and anesthesia-related heart failure can occur. Yale School of Medicine researchers have now developed a quality measure that uses follow-up hospital visits to track the variation in colonoscopy quality among outpatient facilities. [More]
Eisai's Halaven receives FDA approval for treatment of patients with metastatic liposarcoma

Eisai's Halaven receives FDA approval for treatment of patients with metastatic liposarcoma

Eisai Inc. announced today that the U.S. Food and Drug Administration approved Halaven (eribulin mesylate) Injection (0.5 mg per mL) for the treatment of patients with unresectable or metastatic liposarcoma who have received a prior anthracycline-containing regimen. [More]
Halaven (eribulin mesylate) approved for treatment of liposarcoma

Halaven (eribulin mesylate) approved for treatment of liposarcoma

The U.S. Food and Drug Administration today approved Halaven (eribulin mesylate), a type of chemotherapy, for the treatment of liposarcoma (a specific type of soft tissue sarcoma) that cannot be removed by surgery (unresectable) or is advanced (metastatic). This treatment is approved for patients who received prior chemotherapy that contained an anthracycline drug. [More]
Allergan announces publication of VIBERZI Phase III trial results in The New England Journal of Medicine

Allergan announces publication of VIBERZI Phase III trial results in The New England Journal of Medicine

Allergan plc announced today the publication of the positive results of the Phase III trials of VIBERZITM C IV (eluxadoline) for the treatment of irritable bowel syndrome with diarrhea (IBS-D) in the January 21 issue of The New England Journal of Medicine. [More]
Only 3% of GPs fully confident and informed about pancreatic cancer symptoms

Only 3% of GPs fully confident and informed about pancreatic cancer symptoms

Just 3% of GPs who responded to a recent survey, commissioned by Pancreatic Cancer Action, said they felt fully confident and informed about the symptoms of pancreatic cancer, and the difficulty in recognising these was deemed to be the main barrier to diagnosing patients early. [More]
Study looks at long-term effects of psychological therapies in patients with irritable bowel syndrome

Study looks at long-term effects of psychological therapies in patients with irritable bowel syndrome

For some time doctors have known that psychological therapies can reduce the symptoms of irritable bowel syndrome in the short term. [More]
Roche announces availability of cobas HBVassay for use on cobas 4800 System

Roche announces availability of cobas HBVassay for use on cobas 4800 System

Roche announced today the commercial availability of the cobas HBVassay for use on the cobas 4800 System in countries accepting the CE mark. This new molecular diagnostic assay expands the available virology menu on the cobas 4800 System, improving system efficiency and providing testing flexibility that allows physicians to assess a patient's response to antiviral therapy. [More]
Enteric nerves of irritable bowel syndrome patients respond poorly to inflammatory substances

Enteric nerves of irritable bowel syndrome patients respond poorly to inflammatory substances

For the first time, biopsies of patients with irritable bowel syndrome have shown that the nerves in their gut wall respond poorly to a cocktail of inflammatory substances. This refutes the previous theory that patients with irritable bowel syndrome have an overly sensitive gut. [More]
Endoscopic submucosal dissection appears to be effective treatment for patients with throat cancer

Endoscopic submucosal dissection appears to be effective treatment for patients with throat cancer

According to a study in the December issue of GIE: Gastrointestinal Endoscopy, the monthly peer-reviewed scientific journal of the American Society for Gastrointestinal Endoscopy, endoscopic submucosal dissection (ESD) appears to be a safe and effective minimally invasive treatment for patients with superficial pharyngeal (throat) cancer. [More]
Acupuncture may be safe, effective treatment for chronic pain in pediatric patients

Acupuncture may be safe, effective treatment for chronic pain in pediatric patients

It is upsetting to see anyone in pain, but it's especially heartbreaking to watch a child endure chronic pain. In addition to the suffering itself, chronic pain can cause traumatic effects on a child's quality of life, and it can have significant physical, psychological and social consequences. Making matters worse, chronic pain greatly can affect the child's parents or caregivers by causing feelings of helplessness and inadequacy. [More]
Lexicon announces top-line results from TELECAST Phase 3 study of telotristat etiprate

Lexicon announces top-line results from TELECAST Phase 3 study of telotristat etiprate

Lexicon Pharmaceuticals, Inc. announced today that top-line data from its TELECAST Phase 3 study showed results of telotristat etiprate in treating carcinoid syndrome in cancer patients with metastatic neuroendocrine tumors consistent with the clinical benefit observed in its pivotal TELESTAR study. [More]
Personalised peptide vaccination promising in bladder cancer

Personalised peptide vaccination promising in bladder cancer

Metastatic bladder cancer patients who have progressed on first-line platinum-based chemotherapy could derive survival benefits from personalised peptide vaccination, according to phase II trial results. [More]
Researchers receive $6 million to further develop potential treatment for cocaine abuse

Researchers receive $6 million to further develop potential treatment for cocaine abuse

University of Kentucky College of Pharmacy Professor Chang-Guo Zhan, along with fellow UK Professors Fang Zheng and Sharon Walsh, and Professor Mei-Chuan Ko from Wake Forest University, recently received $6 million in funding over five years to further develop a potential treatment for cocaine abuse. [More]
Race/ethnicity disparities, hospital factors affect analgesic use at US EDs

Race/ethnicity disparities, hospital factors affect analgesic use at US EDs

Minority patients are less likely to receive analgesic medications for abdominal pain at US emergency departments (EDs), suggests a nationwide study in the December issue of Medical Care. [More]
Minority patients seeking care in ED less likely to receive analgesic medication

Minority patients seeking care in ED less likely to receive analgesic medication

New research indicates that minority patients seeking care in the emergency department were 22-30 percent less likely than white patients to receive analgesic medication. [More]
AACR rapid and dramatic responses in TRK fusion patients

AACR rapid and dramatic responses in TRK fusion patients

Loxo Oncology, Inc., a biopharmaceutical company innovating the development of highly selective medicines for patients with genetically defined cancers, today announced new results from its Phase 1 open-label, dose-escalation trial of LOXO-101, a selective inhibitor of tropomyosin receptor kinase (TRK) signaling molecules, and the first preclinical data for its RET and FGFR programs. The data are being presented at the 2015 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Boston. [More]

Novel enzyme therapy offers possible treatment for cocaine overdose

A long-acting enzyme that rapidly and safely metabolizes cocaine in the blood stream is currently being investigated in animal models as a possible treatment for cocaine overdose. [More]
Lexicon's telotristat etiprate improves social and physical function, emotional well-being in cancer patients

Lexicon's telotristat etiprate improves social and physical function, emotional well-being in cancer patients

Lexicon Pharmaceuticals, Inc.'s telotristat etiprate, the first oral therapy in development for the treatment of carcinoid syndrome (CS), was associated with patient-reported improvements in social and physical function and emotional well-being according to new exit interview data from the Phase 3 TELESTAR study presented at the 2015 Neuroendocrine Tumor Society Annual Symposium in Austin, Texas. [More]
Computers can be as good as doctors and nurses in predicting patient discharges

Computers can be as good as doctors and nurses in predicting patient discharges

A computer can do as good a job of predicting how many patients will be discharged from a hospital unit on a given day as doctors and nurses can, according to new research from the University of Maryland's Robert H. Smith School of Business and Johns Hopkins University. In some cases, the computer does even better. [More]
Advertisement
Advertisement